AIDS-related non-Hodgkin's lymphoma: Etiology, epidemiology, and impact of highly active antiretroviral therapy

Leukemia and Lymphoma

Volumn 44, Issue SUPPL. 3, 2003, Pages

  Little, Richard F ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

AIDS related non Hodgkin's lymphoma; Epidemiology; Etiology; HAART

Indexed keywords

ANTIRETROVIRUS AGENT; BLEOMYCIN; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; INDINAVIR; LAMIVUDINE; METHOTREXATE; PREDNISONE; RITUXIMAB; STAVUDINE; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; CARCINOGENESIS; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FATALITY; DRUG INFUSION; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HERPES VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOPROLIFERATIVE DISEASE; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TUMOR CLASSIFICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; PROGNOSIS; TREATMENT OUTCOME;

EID: 1042280333     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190310001623748     Document Type: Review

References (57)

1. Gaspar, B., Sharifi, R., Kinnon, C. et al. (2001) Sap gene transfer restores cytotoxic function in EBV-CTLS generated from individuals with XLP. Paper presented at American Society of Hematology, San Francisco, 2001.
2. Rezza, G. (2000) "Immunosuppression, timing of human herpesvirus 8 infection, and risk of Kaposi's sarcoma among human immunodeficiency virus type 1-infected persons and transplant recipients", Journal of Infectious Diseases, 182, 1809-1810.
3. Nagy, S., Gyulai, R., Kemeny, L., Szenohradszky, P. and Dobozy, A. (2000) "Iatrogenic Kaposi's sarcoma: HHV8 positivity persists but the tumors regress almost completely without immunosuppressive therapy", Transplantation, 69, 2230-2231.
4. Gruhn, B., Meerbach, A., Häfer, R., et al. (2001) Early diagnosis and pre-emptive therapy of Epstein-Barr virus-associated lymphoproliferative disease following hematopoietic stem cell transplantation. Paper presented at American Society of Hematology, Orlando, 2001.
5. Savoldo, B., Gross, J., Karpen, S., et al. (2002) Humanized anti-CD20 monoclonal antibody for the treatment of lymphoproliferative disease developing in pediatric solid organ transplant recipients. Paper presented at Sixth International Conference on Malignancies in AIDS & Other Immunodeficiencies: Basic, Epidemiologic & Clinical Research, Bethesda, April 22-24, 2002.
6. Liu, Z., Savoldo, B., Huls, H., Lopez, T., Gee, A., Wilson, J., et al. (2002) "Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas", Recent Results in Cancer Research, 159, 123-133.
7. Kamel, O.W., van de Rijn, M., Weiss, L.M., Del Zoppo, G.J., Hench, P.K., Robbins, B.A., et al. (1993) "Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoids arthritis and dermatomyositis", New England Journal of Medicine, 328, 1317-1321.
8. Speight, P.M., Jordan, R., Colloby, P., Nandha, H. and Pringle, J.H. (1994) "Early detection of lymphomas in Sjogren's syndrome by in situ hybridisation for kappa and lambda light chain mRNA in labial salivary glands", European Journal of Cancer. Part B, Oral Oncology, 30B, 244-247.
9. Levine, A.M., Shibata, D., Sullivan-Halley, J., Nathwani, B., Brynes, R., Slovak, M.L., et al. (1992) "Epidemiological and biological study of acquired immunodeficiency syndrome-related lymphoma in the County of Los Angeles: preliminary results", Cancer Research, 52 (19 Suppl.), 5482s-5484s.
10. Knowles, D.M. (1996) "Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma", Hematology/Oncology Clinics of North America, 10, 1081-1109.
11. Levine, A.M. (1992) "AIDS-associated malignant lymphoma", Medical Clinics of North America, 76, 253-268.
12. Gaidano, G., Pastore, C., Lanza, C., Mazza, U. and Saglio, G. (1994) "Molecular pathology of AIDS-related lymphomas. Biologic aspects and clinicopathologic heterogeneity", Annals of Hematology, 69, 281-290.
13. Carbone, A., Gloghini, A., Larocca, L.M., Capello, D., Pierconti, F., Canzonieri, V., et al. (2001) "Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas", Blood, 97, 744-751.
14. Ballerini, P., Gaidano, G., Gong, J., Tassi, V., Saglio, G., Knowles, D.M., et al. (1992) "Molecular pathogenesis of HIV-associated lymphomas", AIDS Research and Human Retroviruses, 8, 731-735.
15. Ballerini, P., Gaidano, G., Gong, J.Z., Tassi, V., Saglio, G., Knowles, D.M., et al. (1993) "Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma", Blood, 81, 166-176.
16. Carbone, A., Gaidano, G., Gloghini, A., Larocca, L.M., Capello, D., Canzonieri, V., et al. (1998) "Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas", Blood, 91, 747-755.
17. Delecluse, H.J., Raphael, M., Magaud, J.P., Felman, P., Alsamad, I.A., Bornkamm, G.W., et al. (1993) "Variable morphology of human immunodeficiency virus-associated lymphomas with c-myc rearrangements", The French Study Group of Pathology for Human Immunodeficiency Virus-Associated Tumors, I. Blood, 82, 552-563.
18. Schlaifer, D., Brousset, P., Attal, M., Massip, P., Payen, C., Marchou, B., et al. (1994) "bcl-2 proto-oncogene and Epstein-Barr virus latent membrane protein-1 expression in AIDS-related lymphoma", Histopathology, 25, 77-82.
19. Gaidano, G., Pastore, C. and Volpe, G. (1995) "Molecular pathogenesis of non-Hodgkin lymphoma: a clinical perspective", Haematologica, 80, 454-472.
20. Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, R.I., et al. Lymphoma/Leukemia Molecular Profiling Project. (2002) "The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma", New England Journal of Medicine, 346, 1937-1947.
21. Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., et al. (2000) "Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling", Nature, 403, 503-511.
22. Gascoyne, R.D., Adomat, S.A., Krajewski, S., Krajewska, M., Horsman, D.E., Tolcher, A.W., et al. (1997) "Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma", Blood, 90, 244-251.
23. Kramer, M.H., Hermans, J., Wijburg, E., Philippo, K., Geelen, E., van Krieken, J.H., et al. (1998) "Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma", Blood, 92, 3152-3162.
24. King, J.T. Jr, Justice, A.C., Roberts, M.S., Chang, C.C. and Fusco, J.S. Collaboration in HIV Outcomes Research-US Program Team(2003) "Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era", Medical Decision Making, 23, 9-20.
25. Besson, C., Goubar, A., Gabarre, J., Rozenbaum, W., Pialoux, G., Chatelet, F.P., et al. (2001) "Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy", Blood, 98, 2339-2344.
26. Kalter, S.P., Riggs, S.A., Cabanillas, F., Butler, J.J., Hagemeister, F.B., Mansell, P.W., et al. (1985) "Aggressive non-Hodgkin's lymphomas in immunocompromised homosexual males", Blood, 66, 655-659.
27. Ziegler, J.L., Drew, W.L., Miner, R.C., Mintz, L., Rosenbaum, E., Gershow, J., et al. (1982) "Outbreak of Burkitt's-like lymphoma in homosexual men", Lancet, 2, 631-633.
28. Pluda, J.M., Venzon, D.J., Tosato, G., Lietzau, J., Wyvill, K., Nelson, D.L., et al. (1993) "Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy", Journal of Clinical Oncology, 11, 1099-1107.
29. Dana, B.W., Dahlberg, S., Miller, T.P., Hartsock, R.J., Balcerzak, S., Coltman, C.A., et al. (1990) "m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial", Journal of Clinical Oncology, 8, 1155-1162.
30. Walsh, C., Wernz, J.C., Levine, A., Rarick, M., Willson, E., Melendez, D., et al. (1993) "Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma", Journal of Acquired Immune Deficiency Syndromes, 6, 265-271.
31. Levine, A.M., Wernz, J.C., Kaplan, L., Rodman, N., Cohen, P., Metroka, C., et al. (1991) "Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial", Journal of the American Medical Association, 266, 84-88.
32. Kaplan, L.D., Straus, D.J., Testa, M.A., Von Roenn, J., Dezube, B.J. and Cooley, T.P. (1997) "Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group", New England Journal of Medicine, 336, 1641-1648.
33. Fisher, R.I., Gaynor, E.R., Dahlberg, S., Oken, M.M., Grogan, T.M., Mize, E.M., et al. (1993) "Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma", New England Journal of Medicine, 328, 1002-1006.
34. Wilson, W.H. (1997) Chemotherapy for AIDS-related lymphomas [letter; comment]. New England Journal of Medicine, 337, 1172-1173; discussion 1173-1174.
35. Ratner, L., Redden, D., Hamzeh, F., et al. (1999) Chemotherapy for HIV-NHL in combination with HAART. Paper presented at 3rd National AIDS Malignancy Meeting; Bethesda, May 26-28, 1999.
36. Antinori, A., Cingolani, A., Alba, L., Ammassari, A., Serraino, D., Ciancio, B.C., et al. (2001) "Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy", Aids, 15, 1483-1491.
37. Levine, A.M., Sullivan-Halley, J., Pike, M.C., Rarick, M.U., Loureiro, C., et al. (1991) "Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival", Cancer, 68, 2466-2472.
38. Straus, D.J., Huang, J., Testa, M.A., Levine, A.M. and Kaplan, L.D. (1998) "Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142 - low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases", Journal of Clinical Oncology, 16, 3601-3606.
39. Vaccher, E., Spina, M., di Gennaro, G., Talamini, R., Nasti, G., Schioppa, O., et al. (2001) "Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma", Cancer, 91, 155-163.
40. Ratner, L., Lee, J., Tang, S., Redden, D., Hamzeh, F., Herndier, B., et al. AIDS Malignancy Consortium. (2001) "Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy", Journal of Clinical Oncology, 19, 2171-2178.
41. Spina, M., Vaccher, E., Juzbasic, S., Milan, I., Nasti, G., Talamini, R., et al. (2001) "Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients", Cancer, 92, 200-206.
42. Tirelli, U., Spina, M., Jaeger, U., Nigra, E., Blanc, P.L., Liberati, A.M., et al. (2002) "Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study", Recent Results in Cancer Research, 159, 149-153.
43. Mackall, C.L., Fleisher, T.A., Brown, M.R., Magrath, I.T., Shad, A.T., Horowitz, M.E., et al. (1994) "Lymphocyte depletion during treatment with intensive chemotherapy for cancer", Blood, 84, 2221-2228.
44. Phenix, B.N., Lum, J.J., Nie, Z., Sanchez-Dardon, J. and Badley, A.D. (2001) "Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss", Blood, 98, 1078-1085.
45. Mellors, J.W., Rinaldo, C.R. Jr, Gupta, P., White, R.M., Todd, J.A. and Kingsley, L.A. (1996) "Prognosis in HIV-1 infection predicted by the quantity of virus in plasma", Science, 272, 1167-1170.
46. Vaccher, E., Spina, M., Santarossa, S., et al. (1998) Concomitant CHOP chemotherapy (CT) and highly active antiretroviral therapy (HAART) in patients with HIV-related non-Hodgkin's lymphoma (HIV-NHL). Paper presented at International Conference on AIDS, Geneva, 1998.
47. Little, R.F., Pittaluga, S., Grant, N., Steinberg, S.M., Kavlick, M.F., Mitsup, H., et al. (2003) "Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology", Blood, 101, 4653-4659.
48. Raphael, M., Lamine, M., Abd Alsamad, I., Debre, P. and Binet, J.L. (1992) "Non-Hodgkin's lymphoma and AIDS: histopathologic features", Archives d'anatomie et de Cytologie Pathologique, 40, 105-109.
49. Bauer, K.D., Merkel, D.E., Winter, J.N., Marder, R.J., Hauck, W.W., Wallemark, C.B., et al. (1986) "Prognostic implications of ploidy and proliferative activity in diffuse large cell lymphomas", Cancer Research, 46, 3173-3178.
50. Miller, T.P., Grogan, T.M., Dahlberg, S., Spier, C.M., Braziel, R.M., Banks, P.M., et al. (1994) "Prognostic significance of the Ki67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial", Blood, 83, 1460-1466.
51. Wilson, W.H., Teruya-Feldstein, J., Fest, T., Harris, C., Steinberg, S.M., Jaffe, E.S., et al. (1997) "Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas", Blood, 89, 601-609.
52. Tulpule, A., Sherrod, A., Dharmapala, D., Young, L.L., Espina, B.M., Sanchez, M.N., et al. (2002) "Multidrug resistance (MDR-1) expression in aids-related lymphomas", Leukemia Research, 26, 121-127.
53. Lai, G.M., Chen, Y.N., Mickley, L.A., Fojo, A.T. and Bates, S.E. (1991) "P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines", International Journal of Cancer, 49, 696-703.
54. Kaplan, L. (2003) No benefit from rituximab in a randomized phase iii trial of CHOP with or without rituximab for patients with HIV-associated non-Hodgkin's lymphoma: AIDS Malignancies Consortium Study 101. Paper presented at The Seventh International Conference on Malignancies in AIDS and Other Immunodeficiencies; Bethesda, April 28-29, 2003.
55. Vose, J.M., Link, B.K., Grossbard, M.L., Czuczman, M., Grillo-Lopez, A., Gilman, P., et al. (2001) "Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma", Journal of Clinical Oncology, 19, 389-397.
56. Gutierrez, M., Grossbard, M., Little, R., et al. (2000) Dose-adjusted EPOCH chemotherapy (CT) and rituximab (EPOCH-R): an effective regimen in poor prognosis aggressive B-cell non-Hodgkin's lymphoma (NHL). Paper presented at 36th Annual Proceedings of the American Society of Clinical Oncology, New Orleans, 2000.
57. Mackall, C.L., Fleisher, T.A., Brown, M.R., Andrich, M.P., Chen, C.C., Feuerstein, I.M., et al. (1995) "Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy", New England Journal of Medicine, 332, 143-149.